Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, has announced its participation in the Stifel Virtual Inflammation & Immunology Summit on September 17 & 18. The company will present on Tuesday, September 17, at 1:00 pm PT / 4:00 pm ET, providing an overview of its:
- Multi-cytokine inhibitor programs and platform
- Focus on dermatological and gastrointestinal indications
- Ongoing development of itolizumab in partnership with Ono Pharmaceutical
- Ono's pending option exercise decision to potentially acquire Equillium's rights to itolizumab
Management will be available for one-on-one meetings during the conference. A webcast of the presentation will be accessible on the company's website, with an archived replay available for 90 days.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders, has announced an inducement grant to a new employee. The Compensation Committee of Equillium's Board of Directors granted a nonstatutory stock option to purchase 10,000 shares of common stock under the company's 2024 Inducement Plan on August 30, 2024.
The stock option has an exercise price of $1.07 per share, equal to Equillium's closing stock price on the grant date. It will vest over four years, with 25% vesting on the one-year anniversary and the remaining balance vesting monthly over 36 months, subject to the employee's continued service. This grant was approved in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the new employee's employment.
Equillium (Nasdaq: EQ), a clinical-stage biotech company, announced its participation in two major healthcare conferences: the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference. At these events, Equillium's management will present an overview of their multi-cytokine inhibitor programs and platform, focusing on dermatological and gastrointestinal indications. They will also discuss the ongoing development of itolizumab in partnership with Ono Pharmaceutical.
The Wells Fargo conference presentation is scheduled for September 5 at 4:30 pm ET, while the H.C. Wainwright conference presentation will take place on September 10 at 8:00 am ET. Both presentations will be available via webcast on Equillium's website, with replays accessible for 90 days. The company will also be available for one-on-one meetings during both conferences.
Equillium Inc. (Nasdaq: EQ) reported Q2 2024 financial results and provided corporate updates. Key highlights include:
- Cash balance of $33.3 million at Q2 end, up $1.0 million from Q1
- Revenue of $13.9 million, compared to $9.1 million in Q2 2023
- Net income of $0.5 million, or $0.01 per share, vs. net loss of $3.3 million in Q2 2023
- Positive interim analysis of Phase 3 EQUATOR study for itolizumab in acute graft-versus-host disease
- Positive topline data from Phase 1b EQUALISE study in lupus nephritis and Phase 2 study of EQ101 in alopecia areata
Ono Pharmaceutical's option exercise period for itolizumab rights was triggered, with a decision expected by October 2024. If exercised, Equillium would receive approximately $35 million upfront and be eligible for up to $101.4 million in milestone payments.
Equillium (Nasdaq: EQ) announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). The IDMC reviewed unblinded data from over 100 patients through Day 29 of treatment and recommended the study continue without modifications. This outcome triggers a 90-day period for Ono Pharmaceutical to exercise its option to acquire Equillium's rights to itolizumab for JPY 5 billion (approximately $35 million) plus potential milestone payments of up to $101.4 million. Equillium CEO Bruce Steel expressed optimism about itolizumab's potential benefit for aGVHD patients, where mortality rates are high and first-line treatment remains high-dose corticosteroids.
Equillium Inc (Nasdaq: EQ), a clinical-stage biotech company, has announced its estimated Q2 2024 financial position. The company's cash, cash equivalents, and short-term investments totaled approximately $33.3 million at the end of Q2, marking an increase of about $1.0 million from Q1 2024. This increase is primarily attributed to a $2.7 million tax credit received from the Australian tax authority for 2023 R&D expenses.
Equillium plans to release its complete Q2 2024 financial results around August 8. The company emphasizes that these figures are preliminary and subject to final adjustments. The data has not been audited or reviewed by an independent accounting firm and should not be considered a substitute for official financial statements.
Equillium (Nasdaq: EQ), a clinical-stage biotech firm focused on autoimmune and inflammatory disorders, will participate in two upcoming investor conferences in July. The Leerink Partners Therapeutic Forum in Boston on July 9-10 will feature one-on-one investor meetings and panel presentations on inflammation and immunology.
Additionally, Equillium will present at the JonesTrading Healthcare Seaside Summit on July 15 at Alila Marea Beach Resort in Encinitas, California. This event will include a corporate presentation on the company's clinical programs and partnership with Ono Pharmaceutical, along with investor meetings. The presentation will be available via webcast on Equillium's website, with an archived replay accessible for 90 days.
Equillium (Nasdaq: EQ), a clinical-stage biotech firm, announced its expected inclusion in the Russell Microcap Index effective July 1, 2024. This follows the Russell annual reconstitution, which ranks the 4,000 largest US stocks by market capitalization. Membership in this index lasts a year and also includes growth and value style indexes. CEO Bruce Steel noted that this will increase Equillium's exposure, benefiting from its recent Phase 2 data on EQ101 for alopecia areata and its partnership with Ono Pharmaceutical.
Equillium announced on May 31, 2024, that its Compensation Committee granted a nonstatutory stock option award to a new employee under the company's 2024 Inducement Plan. This inducement award, approved under Nasdaq Listing Rule 5635(c)(4), consists of 7,200 shares of common stock with an exercise price of $1.50 per share, which matches the closing stock price on May 31, 2024. The vesting schedule for this award spans four years, with 25% vesting after one year and the remainder vesting monthly over the next three years, contingent on the employee's continued service with Equillium.
Equillium announced positive topline data from a Phase 2 study of EQ101 in treating alopecia areata (AA), an autoimmune disease causing hair loss. The study indicated favorable safety and tolerability with no serious adverse events (SAEs). Results showed 20% of subjects who completed 24 weeks of treatment reached a SALT score ≤ 20, improving from a baseline SALT of 35 to 100. Among those with moderate to severe AA, 29% achieved a SALT score ≤ 20. EQ101, a multi-cytokine inhibitor targeting IL-2, IL-9, and IL-15, demonstrated promising efficacy, warranting further development and exploration in other dermatological conditions like vitiligo and atopic dermatitis.